Genetic and Epigenetic Silencing of the Beclin 1 Gene in Sporadic Breast Tumors
Overview
Affiliations
Background: Beclin 1, an important autophagy-related protein in human cells, is involved in cell death and cell survival. Beclin 1 mapped to human chromosome 17q21. It is widely expressed in normal mammary epithelial cells. Although down-regulated expression with mono-allelic deletions of beclin 1 gene was frequently observed in breast tumors, whether there was other regulatory mechanism of beclin 1 was to be investigated. We studied the expression of beclin 1 and explored the possible regulatory mechanisms on its expression in breast tumors.
Methods: 20 pairs of tumors and adjacent normal tissues from patients with sporadic breast invasive ductal cancer (IDCs) were collected. The mRNA expression of beclin 1 was detected by real-time quantitative RT-PCR. Loss of heterozygosity (LOH) was determined by real-time quantitative PCR and microsatellite methods. The protein expression of beclin 1, p53, BRCA1 and BRCA2 was assessed by immunohistochemistry. CpG islands in 5' genomic region of beclin 1 gene were identified using MethylPrimer Program. Sodium bisulfite sequencing was used in examining the methylation status of each CpG island.
Results: Decreased beclin 1 mRNA expression was detected in 70% of the breast tumors, and the protein levels were co-related to the mRNA levels. Expression of beclin 1 mRNA was demonstrated to be much higher in the BRCA1 positive tumors than that in the BRCA1 negative ones. Loss of heterozygosity was detected in more than 45% of the breast tumors, and a dense cluster of CpG islands was found from the 5' end to the intron 2 of the beclin 1 gene. Methylation analysis showed that the promoter and the intron 2 of beclin 1 were aberrantly methylated in the tumors with decreased expression.
Conclusions: These data indicated that LOH and aberrant DNA methylation might be the possible reasons of the decreased expression of beclin 1 in the breast tumors. The findings here shed some new light on the regulatory mechanisms of beclin 1 in breast cancer.
Xiang S, Luo Y, Liu W, Tang C, Zhu T, Tian L Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 40087184 DOI: 10.1007/s00210-025-04009-x.
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.
Panda V, Mishra B, Mahapatra S, Swain B, Malhotra D, Saha S Cancers (Basel). 2025; 17(2).
PMID: 39858015 PMC: 11763662. DOI: 10.3390/cancers17020234.
Celada S, Li G, Celada L, Kanagasabai T, Lu W, Brown L Sci Signal. 2024; 17(867):eadk4122.
PMID: 39689183 PMC: 11784317. DOI: 10.1126/scisignal.adk4122.
Gene Expression Regulation and the Signal Transduction of Programmed Cell Death.
Saqirile , Deng Y, Li K, Yan W, Li K, Wang C Curr Issues Mol Biol. 2024; 46(9):10264-10298.
PMID: 39329964 PMC: 11430711. DOI: 10.3390/cimb46090612.
Cell Death: Mechanisms and Potential Targets in Breast Cancer Therapy.
Qian J, Zhao L, Xu L, Zhao J, Tang Y, Yu M Int J Mol Sci. 2024; 25(17).
PMID: 39273650 PMC: 11395276. DOI: 10.3390/ijms25179703.